Battered King picks new CFO after months of questions

Share this article:

King Pharmaceuticals appointed Joseph Squicciarino chief financial officer.
News of the former Revlon CFO's appointment buoyed the troubled company's stocks, battered in recent months by a botched merger and questions over past earnings statements. A bid by Mylan Laboratories to acquire King was scuttled in February after the Bristol, Tenn.-based company said it would have to restate earnings results from 2002 through the first half of 2004. Squicciarino, who worked for
Johnson & Johnson and Bristol- Myers Squibb before joining Revlon, succeeds James Lattanzi, whose retirement was announced in April.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters